Bio-Rad Provides Immunohematology Platforms to South African National Blood Service


HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and the South African National Blood Service (SANBS), a leading provider of blood transfusion services in eight out of nine provinces in South Africa, today announced that they have substantially completed the rollout of Bio-Rad’s IH-500 immunohematology systems across the SANBS network of transfusion medicine laboratories, as part of an exclusive agreement finalized in early 2022.

The IH-500 is a fully automated random-access platform for blood typing and screening, providing transfusion medicine labs with fast and reliable results in a 24/7 environment. In partnership with SANBS, Bio-Rad has to date successfully installed its IH-500 systems across the SANBS network of eighty-six labs and blood banks enabling high-quality and consistent lab testing across the provinces that rely on SANBS to provide blood products and services to South Africa’s citizens.

"The SANBS implementation was a complex project united by a shared purpose,” said Dara Wright, EVP, and President of Bio-Rad’s Clinical Diagnostics Group. “The Bio-Rad and SANBS partnership brings together a prominent provider of blood transfusion medicine with a leading provider of immunohematology products backed by a mission to deliver high-quality transfusion services to patients across South Africa."

"We are delighted to partner with Bio-Rad and utilize its leading immunohematology platforms for compatibility testing”, said Marion Vermeulen, Executive Director of Transfusion Medicine, and Technical Services at SANBS. “We pride ourselves on being trusted to help save lives and now that we have Bio-Rad’s instruments, technical support, and scientific expertise on board, we are confident we can deliver on our mission to provide patients across South Africa with safe, high-quality blood transfusion products and medical services."

BIO-RAD and IH-500 are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 7,900 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit

Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about partnering with SANBS. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, supply chain risks, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contacts:
Anna Gralinska Schram
Corporate Communications
Bio-Rad Laboratories, Inc.

Khensani Mahlangu, Communication Officer
South African National Blood Service
+27 (0) 82 419 0431